sign in sign up
<<
Home , Hematopathology

hematopathology testing

PATIENTS.ANSWERS.RESULTS.

OCTOBER 2018 www.aruplab.com Information in this brochure is current as of October 2018. All content is subject to change. Please contact ARUP Client Services at (800) 522-2787 with any questions or concerns.

ARUP LABORATORIES As a nonprofit, academic institution of the University of Utah and its Department We believe in of , ARUP believes in collaborating, sharing knowledge, and contributing to laboratory science in ways that benefit our clients and their patients. collaborating,

Our test menu is one of the broadest in the industry, encompassing more sharing than 3,000 tests, including highly specialized and esoteric assays. We offer comprehensive testing in the areas of genetics, molecular , , knowledge, and and , among others. contributing ARUP’s clients include many of the nation’s university teaching to laboratory and children’s hospitals, as well as multihospital groups, major commercial laboratories, and group purchasing organizations. We do not compete with our science in ways clients for office business, choosing instead to support clients’ existing test menus by offering highly complex assays and accompanying consultative that provide support so clients can provide exceptional patient care in their local communities. the best value Offering analytics, consulting, and decision support services, ARUP provides clients with the utilization management tools necessary to prosper in this time of for the patient. value-based care. Our UM+ program helps clients control utilization, reduce costs, Together, and improve patient care. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for ARUP and ® Clinical and . its clients will ARUP’s reputation for quality is supported by our ability to meet or exceed the requirements of multiple regulatory and accrediting agencies and organizations. improve patient ARUP participates in the CAP laboratory accreditation program and has CLIA care today and certification through the Centers of Medicare and Medicaid Services. In December 2016, ARUP earned accreditation to the ISO 15189:2012 standard under CAP. in the future.

patients. answers. results. A laboratory test is more than a number; it is a person, an answer, a diagnosis...... HEMATOPATHOLOGY EXPERTISE

The ARUP Hematopathology Laboratory and Hematopathology Division offer diagnostic consultative services and a comprehensive test menu for the evaluation of hematologic disorders. The division consists of nationally and internationally known medical professionals whose expertise spans many different of hematopathology, including , , cytogenetics, coagulation, and molecular diagnostics. An integrated approach is utilized to provide clients with services ranging from test interpretation and selection to comprehensive histomorphologic diagnosis. For information regarding hematopathology consultation, please call (801) 581-5854.

Archana Mishra Agarwal, MD Bo Hong, MD, FACMG Medical Director, Hematopathology and Special Genetics Medical Director, Cytogenetics and Genomic Microarray Dr. Agarwal is an associate professor of pathology at the University of Dr. Hong is an assistant professor of pathology at University of Utah Utah School of . She received her MD at Delhi University in India School of Medicine. She received her MD at Beijing Medical University and was a postdoctoral research scholar at the University of Iowa. She in Beijing, China, and completed a residency in and served as a pathology resident, a hematopathology fellow, and a molecular at People’s , Beijing Medical University, and a clinical genetics pathology fellow at the University of Utah School of Medicine. Dr. cytogenetics at the University of Utah. Her academic interests Agarwal is board certified in hematopathology, anatomic pathology, and include the clinical significance of cytogenetic findings in hematologic . She is also a member of several professional societies, malignancies, particularly in pediatric and treatment-related including the College of American Pathologists and the American Society leukemia. for Clinical Pathology. Dr. Agarwal’s research interests include red-cell enzymopathies, hemoglobinopathies, and molecular hematopathology.

Erica Andersen, PhD, FACMG Kristin Hunt Karner, MD Medical Director, Cytogenetics and Genomic Microarray Medical Director, Hematopathology; Medical Director, Molecular Dr. Andersen is an assistant professor of pathology at the University Oncology; Director, Hematopathology Fellowship Program of Utah School of Medicine. She received her PhD in genetics from the Dr. Karner is an assistant professor of pathology at the University of University of Wisconsin–Madison and completed a clinical cytogenetics Utah School of Medicine. She received her MD from the University of fellowship at the University of Utah. She is board certified by the American Nebraska and completed her anatomic and clinical pathology residency Board of and Genomics and Genomics and is a fellow of at the University of New Mexico. She also completed hematopathology the American College of Medical Genetics and Genomics. Dr. Andersen’s and molecular genetic pathology fellowships at the University of New interests include both constitutional and oncology cytogenetics. She is Mexico and is board certified by the American Board of Pathology in an active member of the Clinical Genome Resource (ClinGen) group’s anatomic and clinical pathology (AP/CP), as well as hematopathology and efforts to improve constitutional structural variant interpretation, and her oncology research molecular genetic pathology. Dr. Karner’s areas of focus include both lymphoid and myeloid projects include improving the diagnosis and monitoring for myelodysplastic syndromes and malignancies, and her current research interests include genetic aspects of myelodysplastic understanding the genetic etiology of rare histiocytic and dendritic cell . syndrome and other myeloid malignancies.

David W. Bahler, MD, PhD Allen N. Lamb, PhD, FACMG Medical Director, Hematopathology Section Chief, Cytogenetics and Genomic Microarray Dr. Bahler is an associate professor of pathology at the University of Utah Dr. Lamb is a professor of clinical pathology at the University of Utah School of Medicine. He is certified by the American Board of Pathology School of Medicine. He received his PhD from Wesleyan University in in clinical pathology, with an added qualification in hematology. Dr. molecular biology and biochemistry. He completed fellowships in clinical Bahler received his PhD in and his MD from the University cytogenetics in the Department of Pediatrics at the University of North of Rochester. His research interests include the role of antigen receptor Carolina and in clinical molecular genetics at Harvard . Dr. stimulation in the development of lymphoid malignancies. Lamb is a founding fellow of the American College of Medical Genetics and Genomics and is certified by the American Board of Medical Genetics and Genomics in clinical cytogenetics. His primary areas of interest are in prenatal and postnatal chromosome diagnosis and the characterization of the phenotypic features (neurodevelopmental and physical development) associated with copy number changes.

Julie Leana Cox, PhD, FACMG K. David Li, MD Medical Director, Cytogenetics Medical Director, Hematopathology Dr. Cox is board certified by the American Board of Medical Genetics and Genomics and Assistant Medical Director, Hematologic Flow Cytometry Genomics and is a diplomate in both clinical cytogenetics and clinical molecular genetics. Dr. Li is an assistant professor of pathology at the University of Utah Dr. Cox received master’s degrees in human genetics and administrative science from Johns School of Medicine. He received his MD from New York Medical College Hopkins University and a doctorate in human genetics from the University of Maryland at and completed a residency in anatomic and clinical pathology at the Baltimore. She completed a clinical cytogenetics and clinical molecular genetics fellowship University of California, San Diego. Dr. Li also completed a fellowship in at the University of Maryland, Division of Human Genetics. hematopathology at the University of Utah, and i s board certified by the American Board of Pathology in anatomic and clinical pathology, with boards in hematology.

Tracy I. George, MD Rodney R. Miles, MD, PhD Executive Director, Clinical Trials and PharmaDx Section Chief, Hematopathology Medical Director, Hematopathology Medical Director, Hematologic Flow Cytometry Dr. George is a professor of pathology at the University of Utah School Dr. Miles is an associate professor of pathology at the University of Utah of Medicine. She completed her MD and residency training in anatomic School of Medicine. He received his MD and a PhD in cell biology from the pathology and laboratory medicine at the University of California San University of Nebraska and is certified by the American Board of Pathology Francisco, with fellowships in hematopathology and in anatomic and clinical pathology, with subspecialty certification in at Stanford University. Dr. George is board certified in anatomic pathology, hematology. His research interests include biological subtypes of adult and clinical pathology, and hematology by the American Board of Pathology. pediatric non-Hodgkin . Dr. Miles is a member the American Her research interests include mast cell and laboratory Society of Hematology, the Society for Hematopathology, and the United hematology. Dr. George has authored more than 100 publications, is Vice President of States and Canadian Academy of Pathology. Scientific Communications for the International Society for Laboratory Hematology, and Co- Editor-in-Chief of the International Journal of Laboratory Hematology. She received the College of American Pathologists Lifetime Achievement Award in 2014.

for more information, visit: HEMATOPATHOLOGY EXPERTISE

Karen Moser, MD George M. Rodgers III, MD, PhD Medical Director, Hemostasis/Thrombosis Medical Director, Hemostasis/Thrombosis Dr. Moser is an assistant professor of pathology at the University of Utah Dr. Rodgers is a professor of medicine and pathology at the University of School of Medicine. She received her M.D. from Saint Louis University Utah School of Medicine. He received his PhD in pharmacology and his MD and subsequently served as a pathology resident and hematopathology from the Tulane University School of Medicine and is certified in internal fellow at the University of Utah School of Medicine. She is certified by medicine by the American Board of Internal Medicine a nd in hematology the American Board of Pathology in anatomic and clinical pathology, with by the American Board of Pathology. Dr. Rodgers is the co-editor of subspecialty certification in hematology. Dr. Moser is a member of several Wintrobe’s Clinical Hematology. professional societies, including the College of American Pathologists (for which she serves as a member of the Standards and Coagulation Resource Committees), American Society for Clinical Pathology, and International Society on Thrombosis and Haemostasis. Her primary research interest is in laboratory hemostasis and thrombosis testing.

Jay L. Patel, MD Roger Schultz, PhD, FACMG Medical Director, Medical Director, Cytogenetics and Molecular Cytogenetics Medical Director, Genomics Dr. Schultz received a master of science in biology at Wayne State University in Detroit and a PhD in genetics at Michigan State University. He completed a postdoctoral fellowship Medical Director, Hematopathology at Stanford University School of Medicine and a cytogenetics fellowship with subsequent Dr. Patel is an associate professor of pathology at the University of Utah American Board of Medical Genetics and Genomics board certification at the University of School of Medicine. He received his MD from the University of Arizona, Texas Southwestern Medical Center in Dallas. Dr. Schultz is a member of several professional completed a residency in anatomic and clinical pathology at the University societies, including the American Society of Human Genetics and Association of Molecular of Utah, and was a hematopathology fellow at Stanford University. He Pathology. His research interests include chromosomal basis of human disease and is certified by the American Board of Pathology in anatomic and clinical development, DNA repair and cancer, and chromosome and genome stability in cancer. pathology, with subspecialty boards in hematology. Dr. Patel’s clinical and research interests are broad and include all aspects of hematopathology, especially next-generation sequencing technologies in the diagnosis and prognostication of hematolymphoid malignancies.

Sherrie L. Perkins, MD, PhD Kristi J. Smock, MD Chief Executive Officer, ARUP Laboratories Medical Director, Hemostasis/Thrombosis Dr. Perkins, CEO of ARUP Laboratories and a professor of pathology at Dr. Smock is an associate professor of pathology and associate program the University of Utah School of Medicine, has been with ARUP and the director of the Pathology Residency Program at the University of Utah University of Utah for over 25 years and has served in numerous leadership School of Medicine. She completed her medical degree, residency, and roles. She is board certified in anatomic pathology and holds a special fellowship training at the University of Utah. She is currently vice president qualification in hematology. She has authored over 200 peer-reviewed of the North American Specialized Coagulation Laboratory Association journal articles and 70 book chapters in hematopathology. She received (NASCOLA) and an editorial board member for Research and Practice in her PhD in biochemistry from the University of Miami, and earned her Thrombosis and Haemostasis. Dr. Smock’s primary research interest is MD and completed her pathology residency at Washington University in laboratory coagulation medicine. St. Louis. She completed her hematopathology fellowship under Dr. Carl Kjeldsberg at the University of Utah.

Denise Quigley, PhD, FACMG Reha Toydemir, MD, PhD, FACMG Medical Director, Cytogenetics Medical Director, Cytogenetics and Genomic Microarray Dr. Quigley received her PhD in molecular and medical genetics at Oregon Health Sciences Dr. Toydemir is an assistant professor of pathology at the University University and completed post-doctoral fellowships in clinical cytogenetics and clinical of Utah, School of Medicine. He was a fellow in cytogenetics at ARUP molecular genetics at the University of North Carolina, Chapel Hill. She is board certified Laboratories and a previous postdoctoral associate in the Human Genetics in clinical cytogenetics and clinical molecular genetics by the American Board of Medical Department at the University of Utah. He completed his PhD in genetics Genetics and Genomics and Genomics. Dr. Quigley is a member of the CAP Cytogenetics at the University of Utah and his MD at the University of Ankara, School of Resource Committee and past-president of the American Cytogenetics Conference. Her Medicine in Turkey. Dr. Toydemir was the recipient of the 2007 James W. research interests include integrated cytogenetic and molecular genetic testing algorithms in Prahl Award for Outstanding Contributions by a Graduate Student in the hematological disease for accurate diagnosis, prognosis, and guided . biological or biomedical science at the University of Utah, and is a member of the American Society of Human Genetics and Turkish Society of Medical Genetics.

Anton Rets, MD, PhD Xinjie Xu, PhD, FACMG Medical Director, Hematopathology Medical Director, Cytogenetics and Genomic Microarray Dr. Rets is an assistant professor of pathology at the University of Medical Director, Molecular Hematopathology/Oncology Utah School of Medicine. He received his MD and PhD at Perm State Dr. Xu is an assistant professor of pathology at the University of Utah, Academy of Medicine in Russia. He served as an anatomical and clinical School of Medicine. She received her PhD in genetics from the University pathology resident at State University of New York Health Science of Wisconsin-Madison and completed a clinical cytogenetics fellowship Center at Brooklyn and a hematopathology fellow at the University of at the University of Wisconsin-Madison and a clinical molecular genetics Utah School of Medicine. Dr. Rets is board certified in hematopathology, fellowship at Boston University. Dr. Xu is a fellow of the American College anatomic pathology, and clinical pathology. He is also a member of several of Medical Genetics and Genomics and a member of several professional professional societies, including the College of American Pathologists societies, including the American Society of Human Genetics and the and the American Society for Clinical Pathology. Dr. Rets’ professional interests are broad American Society of Clinical Pathology. Her research interests include the identification of novel and include red blood cell disorders, non-neoplastic hematology, and precursor lymphoid molecular markers in cancer and the development of novel diagnostic tools for genetic testing. neoplasms. www.aruplab.com/hematopathology 5 TEST CATEGORIES

test # test name diagnostic prognostic pharmacogenetic

Acute Lymphoblastic Leukemia (ALL) 2002647 Acute Lymphocytic Leukemia (ALL) Panel by FISH, Adult X

2002719 Acute Lymphocytic Leukemia (ALL) Panel by FISH, Pediatric X

BCR-ABL1 Fusion, t(9;22)(q34;q11.2) by Chromosome FISH, 2002298 X X X Interphase

2005010 BCR-ABL1 Qualitative with Reflex toBCR-ABL1 Quantitative X X

2005016 BCR-ABL1 Minor (p190), Quantitative X X

2008420 BCR-ABL1 Mutation Analysis by Next-Generation Sequencing X

2002298 CDKN2 p16 Deletion 9p21 by Chromosome FISH, Interphase X

Chromosome Analysis, Bone Marrow with Reflex to Genomic 2007130 X X Microarray

Chromosome Analysis, Leukemic Blood with Reflex to Genomic 2007131 X X Microarray

2006325 Cytogenomic SNP Microarray—Oncology X

ETV6-RUNX1 (TEL-AML1) Fusion, t(12;21)(p13;q22) by Chromosome 2002298 X X FISH, Interphase

Hyperdiploidy with Trisomy 4 and 10 by Chromosome FISH, 2002298 X Interphase

2002298 IGH Rearrangement 14q32 by Chromosome FISH, Interphase X

0055655 Methylenetetrahydrofolate Reductase (MTHFR) 2 Mutations X

2002298 MLL Rearrangement 11q23 by Chromosome FISH, Interphase X

2002298 TCF3 (E2A) Rearrangement 19p13 by Chromosome FISH, Interphase X X Acute Myelogenous Leukemia (AML) 2011132 Panel by FISH X

Acute Myelogenous Leukemia (AML) with Myelodysplastic 2002653 X Syndrome (MDS) or Therapy-Related AML by FISH

CBFB Rearrangement inv(16)(p13.3q22) by Chromosome FISH, 2002298 X X Interphase

2011114 CBFB-MYH11 inv(16) Detection, Quantitative X X

2004247 CEBPA Mutation Detection X

Chromosome Analysis, Bone Marrow with Reflex to Genomic 2007130 X X Microarray

2006325 Cytogenomic SNP Microarray—Oncology X

2014683 LeukoStrat CDx FLT3 Mutation Detection by PCR X X

2006444 IDH1 and IDH2 Mutation Analysis, Exon 4 X

2002437 KIT Mutations in AML by Fragment Analysis and Sequencing X X

2002298 MLL Rearrangement 11q23 by Chromosome FISH, Interphase X

6 for more information, visit: TEST CATEGORIES

test # test name diagnostic prognostic pharmacogenetic

Acute Myelogenous Leukemia (AML), continued 3000066 NPM1 Mutation Detection by RT-PCR, Quantitative X

RUNX1-RUNX1T1 (AML1-ETO) Fusion, t(8;21) (q22;q22) by 2002298 X X Chromosome FISH, Interphase

2010138 RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Detection, Quantitative X X

2005766 WT1 Mutations by Sequencing X

Myeloid Malignancies Mutation Panel by Next-Generation 2011117 X X Sequencing

Myeloid Malignancies Somatic Mutation and Copy Number Analysis 2012182 X X Panel Acute Promyelocytic Leukemia (APL) 2002363 PML-RARA Translocation by FISH X X X

2002871 PML-RARA Translocation, t(15;17) by RT-PCR, Quantitative X X X B- and T- Cell Markers 2006193 B-Cell Clonality Screening (IgH and IgK) by PCR X

2009318 MYD88 L265P Mutation Detection by PCR, Quantitative X

0055567 T-Cell Clonality Screening by PCR X Burkitt Lymphoma 2012710 Aggressive B-Cell Lymphoma FISH Reflex, Tissue X

2010107 BCL6 (3q27) Gene Rearrangement by FISH X

2001538 IGH-MYC Fusion t(8;14) by FISH X

2002345 MYC (8q24) Gene Rearrangement by FISH X

2002298 MYC Rearrangement 8q24 by Chromosome FISH, Interphase X Chronic Lymphocytic Leukemia (CLL) 2002295 Chronic Lymphocytic Leukemia (CLL) Panel by FISH X

0040227 IGHV Mutation Analysis by Sequencing X Chronic Myelogenous Leukemia (CML) BCR-ABL1 Fusion, t(9;22)(q34;q11.2) by Chromosome FISH, 2002298 X X X Interphase

2008420 BCR-ABL1 Mutation Analysis by Next-Generation Sequencing X X

2005017 BCR-ABL1 Major (p210), Quantitative X X

2005016 BCR-ABL1 Minor (p190), Quantitative X X

2005010 BCR-ABL1 Qualitative with Reflex toBCR-ABL1 Quantitative X X

0055655 Methylenetetrahydrofolate Reductase (MTHFR) 2 Mutations X

www.aruplab.com/hematopathology 7 TEST CATEGORIES

test # test name diagnostic prognostic pharmacogenetic

Follicular Lymphoma/Diffuse Large-Cell Lymphoma 2012710 Aggressive B-Cell Lymphoma FISH Reflex, Tissue X

2002298 BCL6 Rearrangement 3q27 by Chromosome FISH, Interphase X

IGH-BCL2 Fusion, t(14;18)(q32;q21) by Chromosome FISH, 2002298 X Interphase

2001536 IGH-BCL2 Fusion, t(14;18) by FISH X Hairy Cell Leukemia BRAF V600E Mutation Detection in Hairy Cell Leukemia by Real-Time 2007132 X PCR, Quantitative Lymphoproliferative Disorders (LPD) 2002650 Lymphoma (Aggressive) Panel by FISH X

2002298 Trisomy 12 by Chromosome FISH, Interphase X Mantle Cell Non-Hodgkins Lymphoma 2002298 IGH Rearrangement by Chromosome FISH, Interphase X

2007226 IGH-CCND1 Fusion, t(11;14) by FISH X

IGH-CCND1 Fusion, t(11;14)(q13;q32) by Chromosome FISH, 2002298 X Interphase Marginal Zone B-Cell Lymphoma 2002298 MALT1 (18q21) gene rearrangement by FISH X Multiple Myeloma 2002294 Multiple Myeloma Panel by FISH X (MDS) 20q Deletion (D20S108) del(20)(q12) by Chromosome FISH, 2002298 X Interphase

5q Deletion (EGR1)/Monosomy 5 del(5)(q31)/-5 by Chromosome 2002298 X FISH, Interphase

7q Deletion (D7S486)/Monosomy 7 del(7)(q31)/-7 2002298 X by Chromosome FISH, Interphase

2002709 Myelodysplastic Syndrome (MDS) Panel by FISH X

2002298 Trisomy 8 by Chromosome FISH, Interphase X

Myeloid Malignancies Mutation Panel by Next-Generation 2011117 X X Sequencing

Myeloid Malignancies Somatic Mutation and Copy Number Analysis 2012182 X X Panel

8 for more information, visit: TEST CATEGORIES

test # test name diagnostic prognostic pharmacogenetic

Myeloproliferative Neoplasms (MPN) 2010673 CALR (Calreticulin) Exon 9 Mutation Analysis by PCR X X

2002378 Eosinophilia Panel by FISH X X

2002357 JAK2 Exon 12 Mutation Analysis by PCR X

0051245 JAK2 Gene, V617F Mutation, Qualitative X

JAK2 Gene, V617F Mutation, Qualitative with Reflex toCALR 2012084 (Calreticulin) Exon 9 Mutation Analysis by PCR with Reflex toMPL X X Codon 515 Mutation Detection by Pyrosequencing, Quantitative

JAK2 Gene, V617F Mutation, Qualitative with Reflex toJAK2 Exon 12 2012085 X Mutation Analysis by PCR

0040168 JAK2 Gene, V617F Mutation, Quantitative X

2005545 MPL Codon 515 Mutation Detection by Pyrosequencing, Quantitative X

2002360 Myeloproliferative Disorders Panel by FISH X

PDGFRA-FIP1L1 Fusion (CHIC2 Deletion) by Chromosome FISH, 2002298 X Interphase

2002298 PDGFRB Rearrangement 5q33.1 by Chromosome FISH, Interphase X

2002298 Trisomy 8 by Chromosome FISH, Interphase X

2002298 Trisomy 9 by Chromosome FISH, Interphase X

Myeloid Malignancies Mutation Panel by Next-Generation 2011117 X X Sequencing

Myeloid Malignancies Somatic Mutation and Copy Number Analysis 2012182 X X Panel Primary Effusion Lymphoma 2002902 Epstein-Barr Virus (EBV) by in situ Hybridization, Paraffin X

HEMATOLOGIC FLOW CYTOMETRY

test # test name

2008003 Leukemia/Lymphoma Phenotyping by Flow Cytometry

0093199 T-Cell Clonality by Flow Cytometry Analysis of TCR V-Beta

0092099 B-Cell CD20 Expression

www.aruplab.com/hematopathology 9 HEMATOPATHOLOGY IHC STAINS

test # test name test # test name

Immunohistochemistry Markers—Stain and Return Immunohistochemistry Markers—Stain and Return 2003439 Anaplastic Lymphoma Kinase 1 (ALK-1) 2003815 CD163 2003442 B Cell Specific Octamer Binding Protein-1 (BOB-1) 2012844 CD200 2004513 BCL-2 2008652 c-MET 2003457 BCL-6 2008622 CXCL13 2003466 BF-1 2003842 Cyclin D1 (SP4) 2003502 CD1a 2003860 Hairy Cell Leukemia (DB.44) 2003505 CD2 (AB75) 2003878 Factor XIIIa (factor XIII) 2003508 CD3 2003908 Glycophorin A 2003511 CD4 (1F6) 2007173 Granzyme B 2003514 CD5 2003932 Herpes Virus 8 2003517 CD7 2003957 IgA 2003520 CD8 2003960 IgD 2003523 CD10 (CALLA) 2003963 IgG 2003526 CD14 2005844 IgG4 2003529 CD15 (Leu M1) 2003966 IgM 2005114 CD19 2003975 IRF4/MUM1 2003532 CD20 (L26, Leu 16) 2003981 Kappa Light Chains 2003535 CD21 (Dendritic Cell) Ki-67 (MIB-1) 2004519 Also available with interpretation: test code 2007182 2003541 CD23 2003984 Lambda Light Chains 2003544 CD25 2013802 Langerin 2003547 CD30 (Ki-1) 2003993 Mast Cell Tryptase 2003553 CD33 2004014 Myeloperoxidase (MPO) 2003556 CD34 (QBEnd/10) 2004061 Oct-2 2003559 CD35 2004067 p21 (WAF1/CIP1) 2003565 CD42b 2004522 p53 2003568 CD43 (L60, Leu 22) 2004082 PAX5 2003571 CD44 2010787 PAX8 2003574 CD45 (LCA) 2004085 PD1 2003586 CD52 (CAMPATH-1) 2012561 SOX11 2003589 CD56 (NCAM) 2004142 TdT 2003592 CD57 (Leu 7) 2010688 TFE3 2003595 CD61 (Platelet Glycoprotein IIIA) 2004148 TIA-1 2003598 CD68 (KP1) 2004160 TRAP 2003800 CD79A 2004172 Ulex Europaeus Agglutinin 1 (UEA-1) 2003806 CD117 (c-Kit) 2004184 Wilms Tumor (WT1), N-terminus 2003809 CD123 2003812 CD138 (Syndecan-1)

10 for more information, visit: www.aruplab.com/hematopathology 11 www.aruplab.com | www.arupconsult.com

ARUP LABORATORIES 500 Chipeta Way Salt Lake City, UT 84108-1221 Phone: (800) 522-2787 Fax: (801) 583-2712 www.aruplab.com

ARUP is a nonprofit enterprise of the University of Utah and its Department of Pathology. © 2018 ARUP Laboratories BD-TS-025, Rev 12, October 2018

12 for more information, visit: